CARDIAC-STAR: prevalence of cardiovascular comorbidities in patients with HR + /HER2 − metastatic breast cancer

CARDIAC-STAR: prevalence of cardiovascular comorbidities in patients with HR + /HER2 − metastatic breast cancer

Abstract Background Cardiovascular (CV) comorbidities and concurrent medications with risk of heart rate-corrected QT interval (QTc) prolongation can impact treatment decisions and safety discussions for patients with breast cancer. However, limited data are available regarding their prevalence in p...

Full description

Saved in:

Bibliographic Details
Main Authors:	Susan Dent, Avirup Guha, Heather Moore, Doris Makari, Rachael McCaleb, Irene Arias, Stella Stergiopoulos, Benjamin Li, Michael Fradley
Format:	Article
Language:	English
Published:	BMC 2025-01-01
Series:	Cardio-Oncology
Subjects:	Cardiovascular comorbidities Cyclin-dependent kinase 4/6 inhibitor HR + /HER2– Medical claims Metastatic breast cancer QTc prolongation
Online Access:	https://doi.org/10.1186/s40959-025-00305-w
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Association between Corrected QT Interval, QT Dispersion and Clinico-biochemical Severity of Diabetic Ketoacidosis in Children Aged 1-12 Years: A Prospective Cohort Study
by: Hamritha Ashokkumar, et al.
Published: (2025-01-01)

Real-World Experience with CDK4/6 Inhibitors in the First-Line Palliative Setting for HR+/HER2− Advanced Breast Cancer
by: Ram Patel, et al.
Published: (2025-01-01)

Updated treatment guidelines for drug-resistant TB: how safe are clofazimine-based regimens?
by: E. Pontali, et al.
Published: (2024-11-01)

PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2− breast cancer
by: Eduardo Terán, et al.
Published: (2024-09-01)

УПРАВЛІННЯ ДІДЖИТАЛІЗАЦІЄЮ HR-ПРОЦЕСІВ В БІЗНЕСІ
by: Вероніка Командровська, et al.
Published: (2024-11-01)

Nomograms for predicting recurrence of HER2‐positive breast cancer with different HR status based on ultrasound and clinicopathological characteristics
by: Xudong Zhang, et al.
Published: (2024-09-01)

Case report: Near-complete response to neratinib-based treatment in HR-positive HER2-amplified metastatic breast cancer refractory to trastuzumab deruxtecan
by: Ünal Metin Tokat, et al.
Published: (2025-01-01)

HR Service Formation and Development as Organization Competitiveness Factor
by: G. G. Biganova, et al.
Published: (2017-09-01)

Digital HR tools and their role in improving the competitiveness of companies
by: V. V. Degtyareva
Published: (2021-07-01)

Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer
by: Paola Zagami, et al.
Published: (2025-02-01)

HR Tech and staff training interaction
by: N. Yu. Kaufman, et al.
Published: (2022-07-01)

Improvement of HR processes as a condition of modernization of personnel policy in the health system
by: A. D. Kaprin, et al.
Published: (2015-06-01)

Tree human resources (HR) model of human resource development in higher education
by: Amir Tengku Ramly, et al.
Published: (2024-03-01)

Discussion on the mechanism of HER2 resistance in esophagogastric junction and gastric cancer in the era of immunotherapy
by: Yan Zhang, et al.
Published: (2025-12-01)

Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
by: Satomi Watanabe, et al.
Published: (2019-03-01)

Monitoring and management of adverse effects associated with trastuzumab deruxtecan: a UAE-specific consensus
by: Emad Dawoud, et al.
Published: (2025-01-01)

Very first real-world data on zongertinib use in non-small cell lung cancer patients with HER2 mutations: A brief report
by: Oliver Illini, et al.
Published: (2024-01-01)

LRP1 involvement in FHIT-regulated HER2 signaling in non-small cell lung cancer
by: Théophile Ponchel, et al.
Published: (2025-03-01)

CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer
by: Lorenzo Castagnoli, et al.
Published: (2025-01-01)

Review of the clinical status of cardiotoxicity of HER-2 positive breast cancer targeted therapeutic drugs
by: Xiang Zhang, et al.
Published: (2025-02-01)

Exploring the Anticancer Potential of MonoHER (7-Mono-O-(β-Hydroxyethyl)-Rutoside): Mitochondrial-Dependent Apoptosis in HepG2 Cells
by: Chujie Li, et al.
Published: (2025-01-01)

IMPROVING QUALITY THROUGH INNOVATIONS: THE ROLE OF VENTURE FINANCING AND HR SUPPORT
by: Doston T. Turgunov, et al.
Published: (2025-03-01)

Impact of HER2-targeting antibody drug conjugates in treatment strategies for patients with breast cancer
by: Hanghang Ma, et al.
Published: (2025-02-01)

Neratinib and the Role of Anti‐HER2 Therapy in Salivary Duct Carcinoma
by: Martina Napolitano, et al.
Published: (2025-01-01)

Size-resolved Compositional Analysis and Source Apportionment of Submicron Aerosol during Lockdown Period Using HR-ToF-AMS
by: Prodip Acharja, et al.
Published: (2022-09-01)

Utilisation of the Innovative [18F]-Labelled Radiotracer [18F]-BIBD-071 Within HR+ Breast Cancer Xenograft Mouse Models
by: Di Fan, et al.
Published: (2025-01-01)

Molecular characterization and potential therapeutic roles of miR125a in HER-2 positive gastric cancer
by: Afraa Mamoori, et al.
Published: (2023-07-01)

Understanding HR attributions and creativity of SMEs employees in Colombia: a qualitative study
by: Lisseth Gutierrez-Gonzalez, et al.
Published: (2025-01-01)

A glimpse into the future: Integrating artificial intelligence for precision HER2‐positive breast cancer management
by: Xinpei Deng, et al.
Published: (2024-09-01)

Establishment of a Rapid and Convenient Fluoroimmunoassay Platform Using Antibodies Against PDL1 and HER2
by: Ji Eun Choi, et al.
Published: (2025-01-01)

Trends in breast cancer among elderly women: Development in estrogen and HER2 subtypes in the last ten years
by: Frederik K. Palshof, et al.
Published: (2025-02-01)

Toward A Smart City Pontianak: A Study of Digital Governance Effectiveness As A Moderator of The Relationship Between Work Culture, HR Management, and Public Satisfaction
by: Sulaiman Sulaiman, et al.
Published: (2024-11-01)

Impact of HER2 Expression on the Prognosis of Muscle-Invasive Bladder Cancer Patients Treated with Bladder-Preservation Comprehensive Therapy
by: Yatong Chen, et al.
Published: (2025-01-01)

Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma
by: Laura Scalambra, et al.
Published: (2025-01-01)

Trifluridine-tipiracil in previously treated patients with oestrogen receptor-positive, HER2-negative metastatic breast cancer (BOOG 2019-01 TIBET trial): a single-arm, multicentre, phase 2 trialResearch in context
by: Niels A.D. Guchelaar, et al.
Published: (2025-02-01)

Systematic Review and Network Meta-Analysis on Treating Hormone Receptor-Positive Metastatic Breast Cancer After CDK4/6 Inhibitors
by: Neha Pathak, et al.
Published: (2025-01-01)

A multicenter retrospective study of early cardiac toxicity in operable breast cancer patients receiving concurrent dual or mono anti-HER2 therapy with postoperative radiation therapy
by: Jing Yang, et al.
Published: (2025-02-01)

Case report: Patients with positive HER-2 amplification locally advanced gastroesophageal junction cancer achieved pathologic complete response with the addition of pembrolizumab to chemotherapy plus trastuzumab as neoadjuvant therapy
by: Huanhuan Li, et al.
Published: (2025-02-01)

The Role of Monetary and Non-Monetary Incentives in the Workplace as Influenced by Career Stage
by: Andrew Ballentine, et al.
Published: (2003-04-01)

Telecommuting as a True Workplace Alternative
by: Kelli A. Green, et al.
Published: (2003-04-01)